Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high- risk population

Blood

Volumn 92, Issue 3, 1998, Pages 737-744

  Richardson, Paul G ^a   Elias, Anthony D ^b   Krishnan, Amrita ^b   Wheeler, Catherine ^b   Nath, Raj ^b   Hoppensteadt, Debra ^b   Kinchla, Nancy M ^b   Neuberg, Donna ^b   Waller, Edmund K ^b   Antin, Joseph H ^b   Soiffer, Robert ^b   Vredenburgh, James ^b   Lill, Michael ^b   Woolfrey, Ann E ^b   Bearman, Scott I ^b   Iacobelli, Massimo ^b   Fareed, Jawed ^b   Guinan, Eva C ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEFIBROTIDE; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL CRAMP; ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG USE; FEMALE; FIBRINOLYTIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MALE; MULTIPLE ORGAN FAILURE; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT INDICATION; VEIN OCCLUSION;

ADOLESCENT; ADULT; BILIRUBIN; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION; FEASIBILITY STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HEPARIN; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MULTIPLE ORGAN FAILURE; NEOPLASMS; PALLIATIVE CARE; POLYDEOXYRIBONUCLEOTIDES; RECEPTORS, PURINERGIC P1; RETROSPECTIVE STUDIES; RISK; THALASSEMIA; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0032147122     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562,1988
2. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED: Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 4:116,1984
3. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255,1993
4. Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 85:3005,1995
5. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP: Hepatic venocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 8:1699,1990
6. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R: Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778,1987
7. Blostein MD, Paltiel OB, Thibault A, Rbka WB: A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant 10:439,1992
8. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB: Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 11:1729,1993
9. Shulman HM, Gown AM, Nugent DJ: Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 127:549,1987
10. Rollins BJ: Hepatic veno-occlusive disease. Am J Med 81:297,1986
11. Shulman HM, Fisher LB, Schoch HG, Kenne KW, McDonald GB: Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 19:1171,1994
12. Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D'Agay MF, Gluckman E: Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 63:509,1991
13. Salat C, Holler E, Reinhardt B Kolb HJ, Seeber B, Ledderose G, Mittermueller J, Duell T, Wilmanns W, Hiller E: Parameters of the fibrinolytic system in patients undergoing BMT: Elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 14:747,1994
14. Salat C, Holler E, Hans-Jochem K, Brigitte R, Pihusch R, Wolfgang W, Hiller E: Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood 89:2184,1997
15. Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM: Naturally occuring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver. Blood 81:3458,1993
16. Bearman SI, Shuhart MC, Hinds MS, McDonald GB: Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 80:2458,1992
17. Ibrahim A, Pico JL, Maraninchi D, Zambon E, Attal M, Brault P, Tilly H, Blaise D, Hayat M: Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin El. Bone Marrow Transplant 7:53, 1991 (suppl)
18. Bearman SI, Lee JL, Baron AE, McDonald GB: Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 89:1501,1997
19. Palmer KJ, Goa KL: Defibrotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 45:259,1993
20. Pescador R, Porta R, Ferro L: An integrated view of the activities of defibrotide. Semin Thromb Hemost 22:71,1996
21. Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D, Cedro A, Salvetti L, Mantovani M, Prino G: Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 238:327,1993
22. Bracht F, Schror K: Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 200:933,1994
23. Evangelista V, Piccardoni P, de Gaetano G, Cerletti C: Defibrotide inhibits platelets activation by cathepsin G relased from stimulated polymorphonuclear leukocytes. Thromb Haemost 67:660,1992
24. Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V: Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins 40:337,1990
25. Cirillo F, Margaglione M, Vecchione G, Ames PRJ, Coppola A, Grandone E, Cerbone AM, Marelli C, Di Minno G: In vitro inhibition by defibrotide of monocyte Superoxide anion generation. A possible mechansim for the antithrombotic effect of a polydeoxribonucleotide-derived drug. Haemostasis 21:98,1991
26. Bacher P, Kindel G, Walenga JM, Fareed J: Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug "defibrotide". A dual mechanism in the control of vascular pathology. Thromb Res 70:343,1993
27. Zhou Q, Chu X, Ruan C: Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 71:507,1994
28. Bonomini V, Vangelista A, Frasca GM: A new antithrombotic agent in the treatment of acute renal failure due to hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Nephron 37:144, 1984 (letter)
29. Bonomini V, Frasca GM, Raimondi C, D'arcangelo GL, Vangelista A: Effect of a new antithrombotic agent (Defibrotide) in acute renal failure due to thrombotic microangiopathy. Nephron 40:195,1985
30. Ulutin ON: Antithrombotic effect and clinical potential of defibrotide. Semin Thromb Hemost 19:186,1993
31. Coccheri S, Biagi G: Defibrotide. Cardiovasc Drug Rev 9:172,1991
32. Haire WD, Ruby EI, Gordon BG, Patil KD, Stephens LC, Kotulak GD, Reed EC, Vose JM, Bierman PJ, Kessinger A, Armitage JO: Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA 274:1289,1995
33. Rubenfeld GD, Crawford SW: Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines. Ann Intern Med 125:625,1996
34. Zager RA, O'Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, Stewart P, Thomas ED: Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kid Dis 13:210,1989
35. 2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Arch Pharmacol 331:125,1985
36. Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F: Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 35:151,1988
37. Biagi G, Legnani C, Rodorigo G, Coccheri S: Modulation of arachidonate metabolite generation in human blood by oral defibrotide. Arzneimittelforschung/Drug Res 41:511,1991
38. Di Perri T, Laghi-Pasini F, Ceccatelli L, Pasqui AL: Defibrotide inhibits Ca2+ dependent neutrophil activiation: Implications for its pharmacological activity in vascular disorders. Angiology-J Vase Dis: 971,1991
39. Ferraresso M, Rigotti P, Stepkowski SM, Chou T-C, Kahan BD: Immunosuppressive effects of defibrotide. Transplantation 56:928,1993
40. Fareed J, Callas DD, Hoppensteadt D, Jeske W, Walenga JM: Recent development in antithrombotic agents. Exp Opin Invest Drugs 4:389,1995
41. Fareed J: Modulation of endothelium by heparin and related polyelectrolytes, in Nicolaides A, Novo S (eds): Advances in Vascular Pathology 1997. Amsterdam, The Netherlands, Elsevier Science BV,1997
42. DeLeve LD: Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 24:830,1996